<p>Isomorphic Labs 将利用这笔资金推动其全球领先的人工智能药物设计引擎，扩大其全球业务并推进药物候选管线。</p>
<p>, /PRNewswire/ -- Isomorphic Labs 是一家以人工智能为核心的药物设计和开发公司，今天宣布已完成 21 亿美元的 B 轮融资。这轮投资将加速公司从开创新型人工智能模型到大规模应用的演变。</p>
<p>此次融资轮由 Thrive Capital 主导，现有投资者 Alphabet 和 GV 参与，同时还吸引了新投资者 MGX、淡马锡、CapitalG 和英国主权人工智能基金，显著扩大了 Isomorphic Labs 的全球资本基础。</p>
<p>新资本将用于继续开发和部署 Isomorphic Labs 的人工智能药物设计引擎（IsoDDE），加速和扩展其治疗项目管线向临床的推进。此外，这笔资金将支持我们现有的招聘目标，通过在各个地点整合世界级的人工智能、工程、药物设计和临床人才；这种全球规模对 Isomorphic Labs 长期愿景至关重要，即将人工智能驱动的突破应用于最复杂的生物和医学挑战，并应对全球疾病负担。</p>
<p>这轮融资进一步验证了 Isomorphic Labs 在人工智能药物设计能力方面的进展，并标志着公司一个关键时刻，表明其从第一性原理出发的方法使其能够定义人工智能驱动的药物设计的未来。通过将药物发现重新构想为一个集成的科学和工程学科，以专有的人工智能和数据为核心，Isomorphic Labs 旨在以以前认为不可能的精度和速度实现科学突破。</p>
<p>&#34;人工智能在医疗保健中的应用提供了深远的机会。Isomorphic Labs 在利用人工智能加速药物发现方面已经取得了非凡的进展，我们对这种势头和技术平台的早期前景感到兴奋，&#34; <strong>Alphabet 和 Google 的总裁兼首席投资官 Ruth Porat 表示。</strong>&#34;这一轨迹令人鼓舞，这笔资金将用于加速工作，并以更快的速度将重要干预措施推向市场。&#34;</p>
<p>&#34;这轮融资是来自多元化的顶级国际投资者对我们以人工智能为核心的药物设计和开发方法的巨大信任，&#34; <strong>创始人兼首席执行官 Sir Demis Hassabis 表示。</strong>&#34;现在我们已经证明我们的方法是根本上合理的，我们的重点是将我们的技术扩展到其全部潜力。这笔资金注入使我们能够大规模构建我们的药物设计引擎，推动我们在解决所有疾病的使命中向前迈进。&#34;</p>
<p>&#34;这一里程碑建立在我们人工智能药物设计引擎的实力之上，该引擎已经在我们的内部项目中证明了其价值，通过实现关键里程碑并以前所未有的速度识别可行的候选药物，&#34; <strong>Isomorphic Labs 总裁 Max Jaderberg 表示。</strong>&#34;我们的药物设计引擎有效，并为我们提供了一种可重复的方法来为广泛的疾病设计新药，构建一个以前无法实现的医学未来。&#34;</p>
<p>&#34;我们感到荣幸能够继续支持 Isomorphic 解决所有疾病的使命，&#34; <strong>Thrive Capital 创始人兼首席执行官 Joshua Kushner 表示。</strong>&#34;在过去的一年里，我们对团队的信心只增不减，因为他们在构建一个统一的人工智能药物设计引擎方面取得了显著进展，以定义药物发现和设计的新纪元。&#34;</p>
<p>&#34;Isomorphic 组建的团队素质无与伦比，他们继续验证我们对这是人工智能与药物发现交汇处的顶尖团队的信念，&#34; <strong>GV 的管理合伙人 Dr. Krishna Yeshwant 表示。</strong>&#34;我们对 Isomorphic 充满信心。我们相信他们的方法可以创造重要的药物，这些药物将在早期阶段得到更好的理解，推动以前不可能的边界。&#34;</p>
<p><strong>技术进步与战略影响</strong></p>
<p>Isomorphic Labs 开发了一系列专有的突破性人工智能模型，这些模型共同构成了其统一的人工智能药物设计引擎，能够在多个治疗领域和药物类型中工作。Isomorphic Labs 最近发布了 IsoDDE 强大而广泛的能力的一个子集，突出了其预测准确性，并引入了弥合结构预测与现实世界药物发现之间差距的新能力。IsoDDE 为人工智能药物设计提供了可扩展的基础，提供了在前所未有的准确性下导航新型生物系统所需的预测保真度。</p>
<p>Isomorphic Labs 与诺华、礼来和强生等行业领导者保持着强大的战略合作伙伴关系。这些合作关系作为 Isomorphic 以人工智能为核心的方法的重大验证，体现了其为制药行业带来的实际价值。</p>
<p><strong>关于 ISOMORPHIC LABS</strong></p>
<p>Isomorphic Labs 成立于 2021 年，旨在利用人工智能的力量转变药物发现，开启生物医学突破的新纪元。Isomorphic Labs 由首席执行官 Sir Demis Hassabis 和总裁 Max Jaderberg 领导。Isomorphic Labs 建立了一个世界领先的人工智能药物设计引擎，包含能够在多个治疗领域和药物类型中工作的基础人工智能模型。该公司不断创新模型架构，开发尖端能力以推进药物设计。Isomorphic Labs 总部位于伦敦，在马萨诸塞州剑桥和瑞士洛桑设有办事处。Isomorphic Labs 通过合作项目和全资内部项目推进广泛而雄心勃勃的药物设计组合。有关更多信息，请访问 www.isomorphiclabs.com，并在 LinkedIn 和 X 上关注我们。</p>
<p>媒体咨询</p>
<p>[email protected]</p>
<p>来源：Isomorphic Labs</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9TE41NzQxNSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIwOTU3UFJfTkVXU19VU1BSX19fX19MTjU3NDE1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9TE41NzQxNSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIwOTU3UFJfTkVXU19VU1BSX19fX19MTjU3NDE1"/></p>

1 倍做空谷歌 ETF - Direxion

2 倍做多谷歌 ETF - Direxion

<p>Isomorphic Labs 已经完成了 21 亿美元的 B 轮融资，以增强其人工智能药物设计引擎并扩展全球业务。这轮融资由 Thrive Capital 领投，Alphabet、GV 等参与，将加速其治疗管线的发展并支持顶尖人才的招聘。这项投资验证了 Isomorphic 基于人工智能的药物发现方法，旨在应对复杂的医疗挑战并提高新药上市的速度。该公司已与主要制药公司建立了合作伙伴关系，进一步巩固了其在行业中的地位</p>

<p>Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.</p>
<div class="lb-trans"><p>Isomorphic Labs 将利用这笔资金推动其全球领先的人工智能药物设计引擎，扩大其全球业务并推进药物候选管线。</p>
</div><p>, /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Billion in Series B funding. This latest round of investment will accelerate the company's evolution from pioneering novel AI models to applying them at scale.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Isomorphic Labs 是一家以人工智能为核心的药物设计和开发公司，今天宣布已完成 21 亿美元的 B 轮融资。这轮投资将加速公司从开创新型人工智能模型到大规模应用的演变。</p>
</div><p>The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs' global capital base.</p>
<div class="lb-trans"><p>此次融资轮由 Thrive Capital 主导，现有投资者 Alphabet 和 GV 参与，同时还吸引了新投资者 MGX、淡马锡、CapitalG 和英国主权人工智能基金，显著扩大了 Isomorphic Labs 的全球资本基础。</p>
</div><p>The new capital will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support our existing hiring targets by integrating world-class AI, engineering, drug design, and clinical talent across our sites; this global scale is crucial to Isomorphic Labs' long-term vision of applying AI-driven breakthroughs to the most complex biological and medical challenges and addressing the global burden of disease.</p>
<div class="lb-trans"><p>新资本将用于继续开发和部署 Isomorphic Labs 的人工智能药物设计引擎（IsoDDE），加速和扩展其治疗项目管线向临床的推进。此外，这笔资金将支持我们现有的招聘目标，通过在各个地点整合世界级的人工智能、工程、药物设计和临床人才；这种全球规模对 Isomorphic Labs 长期愿景至关重要，即将人工智能驱动的突破应用于最复杂的生物和医学挑战，并应对全球疾病负担。</p>
</div><p>This funding round serves as further validation of the progress of Isomorphic Labs' AI drug design capabilities and marks a pivotal moment for the company, demonstrating that its first-principles approach positions it to define the future of AI-driven drug design. By reimagining drug discovery as an integrated scientific and engineering discipline with proprietary AI and data at the core, Isomorphic Labs aims to deliver scientific breakthroughs with a level of precision and speed previously thought impossible.</p>
<div class="lb-trans"><p>这轮融资进一步验证了 Isomorphic Labs 在人工智能药物设计能力方面的进展，并标志着公司一个关键时刻，表明其从第一性原理出发的方法使其能够定义人工智能驱动的药物设计的未来。通过将药物发现重新构想为一个集成的科学和工程学科，以专有的人工智能和数据为核心，Isomorphic Labs 旨在以以前认为不可能的精度和速度实现科学突破。</p>
</div><p>&#34;The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform,&#34; <strong>said Ruth Porat, President and Chief Investment Officer Alphabet and Google.</strong>&#34;This trajectory is encouraging, and this funding will be used to accelerate the work and bring important interventions to market with greater speed.&#34;</p>
<div class="lb-trans"><p>&#34;人工智能在医疗保健中的应用提供了深远的机会。Isomorphic Labs 在利用人工智能加速药物发现方面已经取得了非凡的进展，我们对这种势头和技术平台的早期前景感到兴奋，&#34; <strong>Alphabet 和 Google 的总裁兼首席投资官 Ruth Porat 表示。</strong>&#34;这一轨迹令人鼓舞，这笔资金将用于加速工作，并以更快的速度将重要干预措施推向市场。&#34;</p>
</div><p>&#34;This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development,&#34; said <strong>Sir Demis Hassabis, Founder and CEO</strong>. &#34;Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.&#34;</p>
<div class="lb-trans"><p>&#34;这轮融资是来自多元化的顶级国际投资者对我们以人工智能为核心的药物设计和开发方法的巨大信任，&#34; <strong>创始人兼首席执行官 Sir Demis Hassabis 表示。</strong>&#34;现在我们已经证明我们的方法是根本上合理的，我们的重点是将我们的技术扩展到其全部潜力。这笔资金注入使我们能够大规模构建我们的药物设计引擎，推动我们在解决所有疾病的使命中向前迈进。&#34;</p>
</div><p>&#34;This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed,&#34; said <strong>Max Jaderberg, President of Isomorphic Labs</strong>. &#34;Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach.&#34;</p>
<div class="lb-trans"><p>&#34;这一里程碑建立在我们人工智能药物设计引擎的实力之上，该引擎已经在我们的内部项目中证明了其价值，通过实现关键里程碑并以前所未有的速度识别可行的候选药物，&#34; <strong>Isomorphic Labs 总裁 Max Jaderberg 表示。</strong>&#34;我们的药物设计引擎有效，并为我们提供了一种可重复的方法来为广泛的疾病设计新药，构建一个以前无法实现的医学未来。&#34;</p>
</div><p>&#34;We are humbled to have the opportunity to continue to support Isomorphic's mission to solve all disease,&#34; <strong>said Joshua Kushner, Founder and CEO of Thrive Capital.</strong>&#34;Over the past year, our conviction in the team has only deepened as they've made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design.&#34;</p>
<div class="lb-trans"><p>&#34;我们感到荣幸能够继续支持 Isomorphic 解决所有疾病的使命，&#34; <strong>Thrive Capital 创始人兼首席执行官 Joshua Kushner 表示。</strong>&#34;在过去的一年里，我们对团队的信心只增不减，因为他们在构建一个统一的人工智能药物设计引擎方面取得了显著进展，以定义药物发现和设计的新纪元。&#34;</p>
</div><p>&#34;The caliber of the team Isomorphic has assembled is unmatched, and they continue to validate our belief that this is the premier group at the intersection of AI and drug discovery,&#34; said <strong>Dr. Krishna Yeshwant, Managing Partner at GV.</strong>&#34;We have strong confidence in Isomorphic. We believe their approach can create important medicines that will be better understood earlier in the process, pushing the boundaries of what's been possible before.&#34;</p>
<div class="lb-trans"><p>&#34;Isomorphic 组建的团队素质无与伦比，他们继续验证我们对这是人工智能与药物发现交汇处的顶尖团队的信念，&#34; <strong>GV 的管理合伙人 Dr. Krishna Yeshwant 表示。</strong>&#34;我们对 Isomorphic 充满信心。我们相信他们的方法可以创造重要的药物，这些药物将在早期阶段得到更好的理解，推动以前不可能的边界。&#34;</p>
</div><p><strong>Technical Advancement and Strategic Impact</strong></p>
<div class="lb-trans"><p><strong>技术进步与战略影响</strong></p>
</div><p>Isomorphic Labs has developed a number of proprietary breakthrough AI models that together form its unified AI drug design engine that works across multiple therapeutic areas and drug modalities. Isomorphic Labs recently published a subset of the powerful and expansive capabilities of IsoDDE, highlighting its predictive accuracy and introducing new capabilities which bridge the gap between structure prediction and real-world drug discovery. IsoDDE offers a scalable foundation for AI drug design, providing the predictive fidelity required to navigate novel biological systems with unprecedented accuracy.</p>
<div class="lb-trans"><p>Isomorphic Labs 开发了一系列专有的突破性人工智能模型，这些模型共同构成了其统一的人工智能药物设计引擎，能够在多个治疗领域和药物类型中工作。Isomorphic Labs 最近发布了 IsoDDE 强大而广泛的能力的一个子集，突出了其预测准确性，并引入了弥合结构预测与现实世界药物发现之间差距的新能力。IsoDDE 为人工智能药物设计提供了可扩展的基础，提供了在前所未有的准确性下导航新型生物系统所需的预测保真度。</p>
</div><p>Isomorphic Labs maintains a strong portfolio of strategic partnerships with industry leaders like Novartis, Lilly, and Johnson &amp; Johnson. These collaborations serve as a significant validation of Isomorphic's AI-first approach and the tangible value it brings to the pharmaceutical industry.</p>
<div class="lb-trans"><p>Isomorphic Labs 与诺华、礼来和强生等行业领导者保持着强大的战略合作伙伴关系。这些合作关系作为 Isomorphic 以人工智能为核心的方法的重大验证，体现了其为制药行业带来的实际价值。</p>
</div><p><strong>ABOUT ISOMORPHIC LABS</strong></p>
<div class="lb-trans"><p><strong>关于 ISOMORPHIC LABS</strong></p>
</div><p>Isomorphic Labs was founded in 2021, to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Isomorphic Labs is led by CEO Sir Demis Hassabis and President Max Jaderberg. Isomorphic Labs has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in London and has office locations in Cambridge, Massachusetts and Lausanne, Switzerland. Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs. For more information, go to www.isomorphiclabs.com and follow us on LinkedIn and X.</p>
<div class="lb-trans"><p>Isomorphic Labs 成立于 2021 年，旨在利用人工智能的力量转变药物发现，开启生物医学突破的新纪元。Isomorphic Labs 由首席执行官 Sir Demis Hassabis 和总裁 Max Jaderberg 领导。Isomorphic Labs 建立了一个世界领先的人工智能药物设计引擎，包含能够在多个治疗领域和药物类型中工作的基础人工智能模型。该公司不断创新模型架构，开发尖端能力以推进药物设计。Isomorphic Labs 总部位于伦敦，在马萨诸塞州剑桥和瑞士洛桑设有办事处。Isomorphic Labs 通过合作项目和全资内部项目推进广泛而雄心勃勃的药物设计组合。有关更多信息，请访问 www.isomorphiclabs.com，并在 LinkedIn 和 X 上关注我们。</p>
</div><p>For Media Inquiries</p>
<div class="lb-trans"><p>媒体咨询</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE Isomorphic Labs</p>
<div class="lb-trans"><p>来源：Isomorphic Labs</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9TE41NzQxNSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIwOTU3UFJfTkVXU19VU1BSX19fX19MTjU3NDE1" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN57415&amp;Transmission_Id=202605120957PR_NEWS_USPR_____LN57415&amp;DateId=20260512"/></p>

Isomorphic Labs 获得 21 亿美元融资以扩展其 AI 药物设计引擎